The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. Authors marked with an asterisk (*) are participants in ASCO’s Disclosure Management System Pilot; their disclosure is not limited to subject matter under consideration in this article and includes payments to themselves, an immediate family member (I), and/or their institutions (Inst). For information on the pilot program, or to provide feedback, please visit coipilot.asco.org. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.
N. T. Brewer
No relevant relationships to disclose
C. M. Walko
No relevant relationships to disclose
W. K. Chiu
No relevant relationships to disclose
L. G. Dressler
No relevant relationships to disclose
A. Yuen
No relevant relationships to disclose
P. Rubin
No relevant relationships to disclose
O. A. Olajide
No relevant relationships to disclose
S. G. Moore
No relevant relationships to disclose
R. E. Raab
No relevant relationships to disclose
D. R. Carrizosa
No relevant relationships to disclose
S. W. Corso
No relevant relationships to disclose
G. Schwartz
No relevant relationships to disclose
* J. M. Peppercorn
No relevant relationships to disclose
H. L. McLeod
Honoraria - Medco Health Solutions
L. A. Carey
No relevant relationships to disclose
W. J. Irvin
No relevant relationships to disclose